TEL AVIV, Israel, March 31, 2014 /PRNewswire/ -- Tikcro Technologies Ltd. (OTC PK: TIKRF) today reported results for the fourth quarter and fiscal year ended December 31, 2013.
Net loss for the fourth quarter was $436,000, or $0.05 per diluted share. Results for the fourth quarter included a financial loss of approximately $313,000 that resulted primarily from the valuation of Tikcro's holdings in BioCancell Therapeutics, Inc. (TASE: BICL), a clinical-stage biopharmaceutical company engaged with the discovery, development, and commercialization of therapies for treating cancer-related diseases. Excluding this loss, net loss for the fourth quarter was $123,000 or $0.01 per diluted share.
Net profit for the full year ended December 31, 2013 was $8,000, or $0.00 per diluted share. Results for the full year ended December 31, 2013 included a financial gain of approximately $579,000 resulting primarily from the receipt of new shares of BioCancell Therapeutics, Inc., which were awarded to Tikcro pursuant to an arbitration award in July 2013. Excluding this gain, net loss for the full year ended December 31, 2013 was $571,000 or $0.07 per diluted share.
Tikcro supports early stage development in growth areas, with a focus on biotechnology, having projects in several fields originated by researchers from Israeli universities.
About Tikcro Technologies:
Tikcro is seeking early stage growth opportunities.
For more information, visit Tikcro website at www.tikcro.com.
Safe Harbor Statement
Certain of the statements contained herein may be considered forward-looking statements that involve risks and uncertainties including, but not limited to, risks related to our ability to raise financing and the business of BioCancell, including, but not limited to, the development, testing, regulatory approval and commercialization of its products, its intellectual property rights, its funding, its competition, its exposure to lawsuits and its dependence on key suppliers and personnel. Such risks and uncertainties are set forth in the Company's SEC reports, including the Company's Forms 20-F. Actual results may materially differ. Results of operations in any past period should not be considered indicative of the results to be expected for future periods. We undertake no duty to update any forward-looking information.
Tikcro Technologies Ltd.
Condensed Balance Sheets
(US dollars in thousands)
Cash and short-term marketable
Investment in BioCancell
Total current assets
Liabilities and Shareholders' Equity
Other current liabilities
Total liabilities and shareholders'
Tikcro Technologies Ltd.
Statement of Operations
(US dollars in thousands, except per share data)
Three Months Ended
Research and development
General and administrative
Total operating expenses
Financial income (expenses), net
Gain (Loss) before taxes
Net Gain (loss)
Basic and diluted net gain
(loss) per share
Weighted average number of
shares used computing basic
and diluted gain/loss per share
For more information contact:
Jeff Corbin / Rob Fink
KCSA Strategic Communications
(212) 896-1214 / 1206
firstname.lastname@example.org / email@example.com
SOURCE Tikcro Technologies Ltd.